> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/thiamine-basics/thiamine-basics/introduction-to-thiamine/4.-biochemistry/benfotiamine.md).

# benfotiamine

{% hint style="info" %}
**Section:** Complete Biochemistry → Thiamine Derivatives\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026
{% endhint %}

## Summary

**Benfotiamine** is a synthetic thiamine derivative developed in Japan in the late 1950s. Chemically, it is **S-benzoylthiamine O-monophosphate**: a ring-opened form of thiamine with a benzoyl group on the sulfur and a phosphate on the side chain. It is often described as "fat-soluble", but it is actually poorly soluble in both water and oils. It becomes lipophilic only after the gut removes its phosphate group.

Benfotiamine raises **blood thiamine and TPP** more than equivalent amounts of thiamine salts. It is the most clinically studied thiamine derivative. Animal studies show strong protective effects against diabetic complications and neurodegeneration. Human trials show **some short-term symptomatic benefit in diabetic neuropathy** but **no effect on objective outcomes in longer trials so far**. A larger trial in early Alzheimer's disease is ongoing.

## Key facts

| Property                               | Detail                                                                         |
| -------------------------------------- | ------------------------------------------------------------------------------ |
| **Chemical name**                      | S-Benzoylthiamine O-monophosphate                                              |
| **Formula**                            | C₁₉H₂₃N₄O₆PS                                                                   |
| **Molar mass**                         | ≈466.4 g/mol                                                                   |
| **CAS number**                         | 22457-89-2                                                                     |
| **Class**                              | S-acyl (thioester) thiamine derivative with a phosphate ester                  |
| **Solubility**                         | Poor in water and in organic solvents                                          |
| **Activation**                         | Dephosphorylation in gut → S-benzoylthiamine → thioester hydrolysis → thiamine |
| **Main tissues reached (animal data)** | Blood and liver; little or no increase in brain thiamine                       |
| **Largest trial areas**                | Diabetic neuropathy, diabetic nephropathy, Alzheimer's disease                 |

## Absorption and metabolism

{% stepper %}
{% step %}

### Dephosphorylation in the gut

Ecto-alkaline phosphatases on the intestinal brush border remove the phosphate group, producing **S-benzoylthiamine**, which is lipophilic.
{% endstep %}

{% step %}

### Absorption

S-benzoylthiamine crosses the intestinal wall largely by **passive diffusion**, independently of thiamine transporters.
{% endstep %}

{% step %}

### Conversion to thiamine

In the bloodstream, **erythrocytes** and the **liver** hydrolyse the thioester bond (via thioesterases), releasing benzoic acid and the open thiol form, which closes to **thiamine**.
{% endstep %}

{% step %}

### Activation

Thiamine is taken up by tissues through the usual transporters and converted to **TPP** by TPK1.
{% endstep %}
{% endstepper %}

Benzoic acid is conjugated with glycine and excreted as hippuric acid.

## Pharmacokinetics

* Human studies consistently show **higher plasma thiamine and erythrocyte TPP** after benfotiamine than after equivalent amounts of water-soluble thiamine salts.
* In a crossover study of several derivatives, benfotiamine gave the **highest bioavailability**, ahead of fursultiamine and thiamine disulfide.
* A 2014 pharmacokinetic study in healthy volunteers confirmed higher thiamine exposure after benfotiamine than after thiamine hydrochloride.

### Brain delivery

In mice, oral benfotiamine markedly increased thiamine and its phosphate esters in **blood and liver** but produced **no significant increase in brain** thiamine compounds, either after a single dose or after 14 days. Lipid-soluble disulfides such as sulbutiamine, by contrast, do raise brain thiamine in rodents. This is important when interpreting the neurological effects of benfotiamine (see below).

## Proposed mechanisms

| Mechanism                                                     | Description                                                                                                                                                                                                                                                                          |
| ------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **Transketolase activation**                                  | Increased TPP activates transketolase, diverting excess glycolytic intermediates (fructose-6-P, glyceraldehyde-3-P) into the pentose phosphate pathway. This reduces flux into pathways linked to diabetic damage: advanced glycation end products, protein kinase C and hexosamine. |
| **Nrf2 activation**                                           | Activation of the Nrf2/ARE antioxidant pathway                                                                                                                                                                                                                                       |
| **GSK-3β inhibition**                                         | Reduced GSK-3 activity; reduced amyloid plaques and tau phosphorylation                                                                                                                                                                                                              |
| **TPP-independent antioxidant and anti-inflammatory effects** | Effects not explained by TPP increases; possibly due to open-ring metabolites                                                                                                                                                                                                        |

Because benfotiamine raises brain thiamine little in mice yet has neurological effects in mouse models, researchers have proposed that some effects are **independent of thiamine's coenzyme role**. This remains a hypothesis.

## Clinical trials

### Diabetic neuropathy

| Study                                 | Design                                                                                                                                    | Main finding                                                                                                                                                                                   |
| ------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **BEDIP** (2005)                      | 3-week randomized pilot, 40 patients                                                                                                      | Improvement in neuropathy symptom scores, especially pain                                                                                                                                      |
| **BENDIP** (2008)                     | 6-week randomized, double-blind, placebo-controlled; 165 patients; 300 or 600 mg/day                                                      | Improvement in the Neuropathy Symptom Score in the per-protocol population, greater at the higher dose; no significant effect in the intention-to-treat population                             |
| **Type 1 diabetes, 24 months** (2012) | Randomized, double-blind, placebo-controlled; 67 patients; 300 mg/day                                                                     | No effect on peripheral nerve function or soluble inflammatory markers                                                                                                                         |
| **BOND** (results 2026)               | 12-month randomized, double-blind, placebo-controlled; about 60 patients with type 2 diabetes and mild to moderate neuropathy; 600 mg/day | No effect on the primary outcome (corneal nerve fibre length) or on secondary morphological, functional or clinical endpoints; a borderline trend on lower-limb symptom scores; well tolerated |

### Diabetic nephropathy and vascular function

| Study                                     | Design                                                                                             | Main finding                                                                                                |
| ----------------------------------------- | -------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------- |
| **Nephropathy** (2010)                    | 12-week randomized, double-blind, placebo-controlled; 82 patients with type 2 diabetes; 900 mg/day | No reduction in urinary albumin excretion or a kidney injury marker                                         |
| **Post-meal endothelial function** (2006) | Crossover; 13 people with type 2 diabetes                                                          | Benfotiamine prevented impairment of vascular function after a meal rich in advanced glycation end products |

### Alzheimer's disease

| Study                      | Design                                                                                                                                                          | Main finding                                                                                                                                                                                                                                                              |
| -------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Phase IIa pilot** (2020) | 12-month randomized, double-blind, placebo-controlled; 70 people with amnestic mild cognitive impairment or mild Alzheimer's disease; 600 mg/day                | Primary cognitive outcome (ADAS-Cog) showed less decline with benfotiamine, but the difference was **not statistically significant**. Clinical Dementia Rating worsening was significantly reduced, and blood advanced glycation end products were lower. Well tolerated. |
| **BenfoTeam** (ongoing)    | Seamless phase 2a/2b, randomized, double-blind, placebo-controlled; about 400 people with early Alzheimer's disease; 600 or 1,200 mg/day; 72 weeks of treatment | Began 2024; estimated completion December 2027                                                                                                                                                                                                                            |

### Other areas

* **Alcohol dependence:** a randomized trial reported no overall reduction in drinking. Exploratory analyses suggested possible effects in subgroups.
* **Mouse models** of Alzheimer's disease, tauopathy, ALS and other neurodegenerative conditions show benefits. Human evidence in these areas is limited to the trials above.

## Interpreting the evidence

* **Consistent:** benfotiamine raises blood thiamine and TPP and is well tolerated in trials of up to 24 months.
* **Promising but unconfirmed:** symptomatic improvement in short neuropathy trials. Longer trials with objective outcomes have not shown benefit.
* **Unresolved:** effects on cognition. The pilot trial's primary outcome was not significant. The ongoing BenfoTeam trial is designed to answer this question more definitively.
* **Population matters:** most trials enrolled participants **not selected for low thiamine status**. Benefits might differ in people with documented deficiency, as the BOND authors note.

## Safety

Benfotiamine has been well tolerated in published trials, including 600 mg/day for 12 months and 300 mg/day for 24 months. Adverse events were similar to placebo in most studies. Higher doses (1,200 mg/day) are being evaluated for tolerability in the BenfoTeam trial. Long-term safety beyond two years has not been studied in controlled trials.

## Open questions

* Does benfotiamine benefit people with documented low thiamine status more than unselected populations?
* Which metabolites mediate its effects in the brain, given limited brain thiamine increases?
* Will the BenfoTeam trial confirm a cognitive benefit?

## Related pages

* [Thiamine Derivatives (Overview)](broken://pages/42dac8ecc888b0d7e0b1a0677aa37bd14cf30e88)
* [Pentose Phosphate Pathway](broken://pages/565b4d8f50c4e5ebd7b397eb72d1cb62180f4015)
* [Dibenzoylthiamine (DBT)](broken://pages/028b9655a589b82f64b42af63db31b79335b2059)
* [Sulbutiamine](broken://pages/96129eaa0b5447524716179f3914efcb1b77f5f2)

## References

1. Bitsch R, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. *Annals of Nutrition and Metabolism*. 1991;35(5):292–296.
2. Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. *International Journal of Clinical Pharmacology and Therapeutics*. 1998;36(4):216–221.
3. Xie F, et al. Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. *Journal of Clinical Pharmacology*. 2014;54(6):688–695.
4. Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. *BMC Pharmacology*. 2008;8:10.
5. Hammes HP, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nature Medicine*. 2003;9(3):294–299.
6. Pan X, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and β-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. *Brain*. 2010;133(Pt 5):1342–1351.
7. Tapias V, et al. Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. *Human Molecular Genetics*. 2018;27(16):2874–2892.
8. Haupt E, et al. Benfotiamine in the treatment of diabetic polyneuropathy: a three-week randomized, controlled pilot study (BEDIP study). *International Journal of Clinical Pharmacology and Therapeutics*. 2005;43(2):71–77.
9. Stracke H, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. *Experimental and Clinical Endocrinology & Diabetes*. 2008;116(10):600–605.
10. Fraser DA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. *Diabetes Care*. 2012;35(5):1095–1097.
11. Bönhof GJ, et al. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. *BMJ Open*. 2022;12(2):e057142. (Protocol.)
12. BOND trial results. *BMJ Open Diabetes Research & Care*. 2026;14(1):e005773. \[Authors and title to be confirmed.]
13. Alkhalaf A, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. *Diabetes Care*. 2010;33(7):1598–1601.
14. Stirban A, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. *Diabetes Care*. 2006;29(9):2064–2071.
15. Gibson GE, et al. Benfotiamine and cognitive decline in Alzheimer's disease: results of a randomized placebo-controlled phase IIa clinical trial. *Journal of Alzheimer's Disease*. 2020;78(3):989–1010.
16. ClinicalTrials.gov. A trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam). NCT06223360.
17. Manzardo AM, et al. Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. *Drug and Alcohol Dependence*. 2013;133(2):562–570.
18. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. *International Journal of Molecular Sciences*. 2021;22(11):5418.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Doses mentioned are those used in published studies. Suggest corrections or new sources via the feedback link.
{% endhint %}
